2017 American Transplant Congress
Presence of Complement Activating Donor Specific Antibodies Is Associated with Poor Renal Allograft Survival: Two Centre Retrospective Study.
Introduction: Complement fixing donor specific antibodies (DSA) as detected by presence of C3d at the time of rejection is associated with poor graft outcome;no studies…2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…2017 American Transplant Congress
Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents.
Pathology, BioChemistry and Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL
Purpose: To detect markers and novel treatment targets related to fibrogenesis and eventual graft loss by focusing on Epithelial Mesenchymal transition (EMT) which requires understanding…2017 American Transplant Congress
Dual Targeting of Costimulation and Proteasome to Desensitize and Prolong Graft Survival of Sensitized Nonhuman Primates.
[Background] Pre-formed donor-specific anti-HLA antibodies (DSA) from prior transplantation, transfusion, or pregnancy affects a significant portion (35%) of patients awaiting a kidney transplant. Highly sensitized…2017 American Transplant Congress
High Titer De Novo Donor-Specific HLA Alloantibodies and Cardiac Allograft Vasculopathy After Pediatric Heart Transplantation.
Background: Cardiac allograft vasculopathy (CAV) continues to be a limiting factor in long-term survival after pediatric heart transplantation (HT). Criteria for early diagnosis of CAV…2017 American Transplant Congress
Factors Affecting Desensitization Outcome.
The purpose of this study was to identify factors that affect the outcome of desensitization. We reviewed antibody and HLA mismatch data from 114 patients…2017 American Transplant Congress
Accelerated De-Novo Donor-Specific Antibody-Mediated Rejection in a Non-Human Primate Model of Renal Transplantation.
Surgery - Division of Transplantation, University of Wisconsin-Madison, Madison, WI
The development of accelerated antibody-mediated rejection (ABMR) is associated with early allograft dysfunction and premature graft loss. In animals, pre-sensitization is usually required in order…2017 American Transplant Congress
The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis.
Incompatible living donor kidney transplant (ILDKT) has been established as an effective option for patients with willing but human leukocyte antigen incompatible live donors, reducing…2016 American Transplant Congress
Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.
Department of Surgery, Division of Transplant Surgery, Mayo Clinic, Rochester, MN.
Introduction:Plasma cells (PCs) are a major source of alloantibody in transplant patients.They are resistant to current therapy. Since receptor/ligand interactions in the stromal environment are…2016 American Transplant Congress
A Novel Study to Determine the Association of Pre-Transplant Donor Specific Antibody and AT1R Antibody with Kidney Transplant Outcomes Prior to Adoption of Solid Phase Antibody Assays.
University of Wisconsin, Madison.
Background: Studies assessing the risk of pre-transplant antibodies are generally restricted to low levels of donor specific antibody (DSA). Here we analyze pre-transplant HLA DSA,…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 40
- Next Page »